Aus Bio’s Respiratory Project – MD990 – has resulted from the identification of several specific glycoproteins, which have been shown to influence and enhance recovery of injured human respiratory cells.
The MD990 compounds may have a role in hastening recovery from respiratory tract infections, and also in reducing the severity of the post-infectious cough syndrome. The Company has demonstrated that the MD990 compounds, in vitro, have a role in the recovery of respiratory cells following injury. Promising results have been demonstrated in pre-clinical animal models and satisfactory safety and tolerance studies have also been demonstrated. Aus Bio holds both know how and IP (US patent granted) as a result of observations that have occurred in the Company’s laboratories. Aus Bio has formulated a group of compounds which have been shown to improve and/or hasten the recovery and/or viability of damaged respiratory cells through the restoration of sialyl-glycoconjugates on their cells.